Zircaix: A Potential Breakthrough in Kidney Can...

By Rene Pretorius

March 3, 2025

The FDA has accepted the Biologics License Application (BLA) for the TLX250-CDx imaging agent (Zircaix®). This investigational PET imaging tool is designed to diagnose and characterize clear cell renal cell carcinoma (ccRCC), the ...
Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients
Advancing Cancer Treatment: Ivonescimab’s Potential and Strategic Collaborati...
ACS Management Innovations: Transforming Patient Outcomes in Acute Coronary S...
Global Childhood Cancer Access
New Global AIDS Strategy 2030 Aims to End AIDS Threat by 2030
Hypertension Detection: HTN-AI Model for Cardiovascular Risk Stratification
CVD Prevention Models in Sub-Saharan Africa: Insights and Gaps
Lenacapavir HIV Prevention: Approval and Access Strategy Updates
Strengthening Africa Health Partnership
Urgent Call for Enhanced Breast Cancer Africa Control Measures
Journavx Pain Management: FDA Approves New Non-Opioid Treatment for Acute Pain
Engineered Heart Muscle Allografts Show Promise in Heart Repair